A discovery program to develop an AAV-based therapy for nephrotic syndrome (NTX014)
A discovery program to develop a novel platform focused on genetic kidney diseases (NTX077)
Co-founder & Interim CEO
Marc is passionate about creating new biomedical ventures. He is a co-founder and CEO at Senolytic Therapeutics Inc., a pharmaceutical company that develops a novel class of medicines by targeting senescence cells. He also supported investments and strategic partnerships at Life Biosciences Inc. in Europe. Currently, Marc is a strategic advisor at Retinset Therapeutics, Cyclomed, Cebiotex and Origen Ventures. He is a co-founder and Partner at Chasing Science, an early-stage biomedical venture builder. Marc brings experience as advisor and board member for multiple organizations and as co-founder of several companies. Marc gained a PhD in Biochemistry from the University of Oxford in 2006, and a Harvard Business School PLD Program in 2011.
CSO & COO
Gonzalo combines a solid scientific background from his 15 years working in top research centers (CNIO, CRG and IRB Barcelona) with a passionate attitude and hands-on experience in entrepreneurship in the biotechnology sector. Since 2016, he linked his research in the laboratory with the creation of a spin-off whose main objective was to attract private investors to develop an antitumor molecule. He was selected as Project leader of the CaixaImpulse grant (2017 edition) and performed executive training from ESADE “From Science to Business Course”. He also serves as a consultant and venture builder at Chasing Science to support the development of therapeutic programs . He holds a PhD with European distinction in Molecular Biology from Universidad Autónoma de Madrid.
Gene Therapy expert
Renal biology expert
Pediatric nephrologist 1
Pediatric nephrologist 2